Restless legs syndrome: pathophysiology and modern management

Kavitha Nagandla, Somsuhbra De

ABSTRACT
Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is characterised by an irresistible urge to move the legs that significantly affects the quality of life of the patient. Prevalence in the general population is 5–25% and it is twice as prevalent in women as in men. RLS is the most common movement disorder in pregnancy with a fourfold increased risk of developing this disorder later in life. The pathophysiology of RLS is centred on dopaminergic dysfunction, reduced central nervous system iron, genetic linkages, or alteration in neurotransmitters such as hypocretins, endorphins levels and immune dysfunction and inflammatory mechanisms. With the emergence of new evidence, there are changes to the previous treatment recommendations for RLS. There is sufficient evidence to conclude that dopamine agonists such as rotigotine transdermal patch, pramipexole, ropinirole, gabapentin enacarbil, pregabalin and gabapentin are effective in the short-term treatment of RLS and rotigotine, followed by gabapentin enacarbil, ropinirole, pramipexole and gabapentin for long-term treatment. Based on expert consensus, the recommendation for daily RLS is dopamine agonists or gabapentin or low-potency opioids. Levodopa is less preferred for treating daily RLS due to its high risk of augmentation. For intermittent RLS, it is levodopa or dopamine agonists or low-potency opioids or benzodiazepines. For refractory RLS, the choice is to change to gabapentin or a different dopamine agonist, addition of a second agent like gabapentin or benzodiazepine to the existing drug or changing to a dopamine agonist such as ropinirole. Advances in the field of diagnosis and therapeutic recommendations for RLS have been supported by the inclusion of new and existing drugs, thereby providing revised recommendations in the prescription practices. The purpose of this review is to provide an update on the current understanding of the pathophysiology of the disease and to highlight the clinical and scientific advances in the field of diagnosis and therapeutic strategies of this disease.

INTRODUCTION
Restless legs syndrome (RLS), also known as Willis-Ekbom disease,1 is a sensory motor disorder defined as an urge to move the legs that may be accompanied by dysesthesias, which is referred to as an unpleasant, abnormal sensation that appears without any apparent sensory stimulation. These sensations are predominant when at rest or during sleep and are relieved by movement. It can be summarised as ‘movement-responsive quiescent nigrostriatal system dysfunction usually combined with dysesthesias.’2 Although the diagnosis is predominantly based on the clinical features, poor recognition of symptoms or bizarre description of symptoms often leads to delay in the diagnosis or misdiagnosis of this condition. If RLS is undiagnosed or undertreated, it can lead to severe impairment of various functions that significantly affects the quality of life of these patients. The consequences of severe RLS are related to the sleep disruption that has a negative impact on the daily activities of patients. It is estimated that most RLS patients sleep for an average of 5 h a day. The consequences of sleep loss are daytime drowsiness, lack of concentration, depression, difficulties with work and disruption of personal and professional relationships.3 There is considerable progress made in understanding this disorder and numerous controlled studies are available with new and existing drugs, thereby providing revised recommendations in the prescription practices. The purpose of this review is to provide an update on the current understanding of the pathophysiology of the disease and to highlight the clinical and scientific advances in the field of diagnosis and therapeutic strategies of this disease.
CLINICAL FEATURES
The classical presentation of RLS is the discomfort in the legs that occurs at rest and is relieved by movements. The unpleasant sensations are often described by patients as creeping, crawling, pulling, stretching type of pain, often deep-seated and localized below the knee. These symptoms peak at night and may be severe enough to force the patient to get out of bed for relief of symptoms. The sensory and periodic limb movements of sleep (PLMS) are stereotyped flexion movements of the lower, and sometimes, upper extremities, which last for 0.5–5 s and occur every 20–40 s throughout sleep and are invariably diagnostic of RLS. The PLMS symptoms are more predominant in the falling phase of core temperature between midnight and 1 am and less severe in the morning. SEPPLMS symptoms are more predominant in the falling phase of core temperature between midnight and 1 am and less severe in the morning.

Disease with non-specific symptoms. The sensory and periodic limb movements of sleep (PLMS) are stereotyped flexion movements of the lower, and sometimes, upper extremities, which last for 0.5–5 s and occur every 20–40 s throughout sleep and are invariably diagnostic of RLS. The PLMS symptoms are more predominant in the falling phase of core temperature between midnight and 1 am and less severe in the morning.

The important clinical criterion is the presence of circadian pattern of symptoms occurring in the evening or night and absent in the daytime. The circadian pattern of symptoms is related to dopaminergic activity that shows natural circadian fluctuations. This association is confirmed by a study by Poceca et al, in which a circadian rhythm for cerebrospinal fluid (CSF) dopamine and homovanillic acid concentrations in humans was demonstrated with higher levels in the daytime than at nighttime, establishing the role of dopamine in the pathophysiology of the disease.

RLS has significant impact on the quality of life of patients. Severe symptoms are associated with psychological impairments related to sleep disruption; poor concentration; and difficulties with work, travel and social events. As RLS is primarily a subjective disorder, various subjective scales are validated to assess the severity of the disease and its impact on the quality of life. International RLS Rating Scale (IRLS), John Hopkins RLS Severity Scale (JHRLSSS), the RLS-6 scales, and the investigator-based Clinical Global Impressions (CGI) are methods to assess the severity of the disease. The quality of life assessment scales include RLS Quality of Life Instrument (RLS-QLI), Hopkins RLS Quality of Life Questionnaire (RLSQoL), and the RLS Quality of Life Questionnaire (QoL-RLS). In a critical overview on these validated methods by Kohnen et al, it was concluded that besides the availability of these methods to investigate the main effects of RLS, there is still a need for the development of methods to address the consequences of RLS on quality of life functioning areas such as ability to work, poor work performance or days missed at work. The objective measurements include polysomnography, periodic limb movement sleep index (PLMI), Periodic limb movement sleep arousal index (PLMS-AI) and efficiency of sleep.

DIAGNOSIS
The diagnosis of RLS is based on history of the following four diagnostic criteria and physical examination that is invariably normal (unless RLS is associated with secondary conditions). The supportive diagnostic criteria include the presence of positive family history, Periodic leg movements (PLM) and symptomatic relief with dopaminergic therapy.

Diagnostic criteria
The International RLS Study Group identified four essential diagnostic criteria that constitute the gold standard in the diagnosis of RLS as listed in boxes 1 and 2.

Box 1 Essential clinical diagnostic criteria
1. The urge to move the legs that is usually accompanied by unpleasant sensations of leg paraesthesia and dysesthesias
2. The urge to move or unpleasant sensation totally relieved by activity
3. The symptoms that appear are worse at rest and are partially relieved by activity
4. The symptoms are worse in the evening and during the night.

Supportive diagnostic criteria are helpful when there is uncertainty in the diagnosis of RLS. The presence of these supportive criteria may reinforce the diagnosis as listed in box 2.

The circadian pattern of symptoms, as discussed, characteristically differentiates RLS from conditions like arthritis, vascular pain syndrome and lumberadicular pain. Recently, a test called the “Suggested Immobilization Test” (SIT) that supports the clinical diagnosis of RLS was developed. This test has also been used to investigate the circadian pattern of occurrence of RLS symptoms. Martin Michaud et al, in a recent study, investigated the circadian variation of the effects of immobility on symptoms by a 40 min SIT that was repeated every 2 h during the 28 h protocol. The results concluded that worsening of RLS symptoms by immobility is closely linked to their intrinsic circadian variation.

The box 3 lists the common conditions that mimic the symptoms of RLS and their associated clinical features that distinguish them from RLS.

Adapted from Bayard et al.

PATHOPHYSIOLOGY
Even though the majority of cases of primary RLS appear to be idiopathic in origin, there has been considerable advancement in understanding the pathophysiology of RLS. Secondary RLS is encountered in various underlying medical conditions, namely, iron deficiency anaemia, renal failure, and pregnancy.

Primary RLS
Genetics
Forty percent of cases of RLS have a positive family history of dominant inheritance, suggesting a genetic basis for this condition. This syndrome is noted among monozygotic twin pairs with difference in the age and onset of symptoms. In the molecular genetics level, RLS was demonstrated in eight loci (seen in 85% of patients) and 22 q23, 2q33, and 20p13) have been determined by model-based linkage analysis and the recent genome-wide association studies have revealed three genetic loci associated with RLS.
these variants in RLS is con-
fi
da pathological genetic hypothesis for RLS.26 The association of
regions of MEIS1 (2p), LBXCOR1/MAP2K5 (15q), BTBD9
in secondary RLS by Schormair
(ESRD). This is the
associated with RLS in patients with end-stage renal disease
population-based and family-based case control studies in the
fl
ganglia. Some studies have shown reduced, increased and
tomography demonstrated a postsynaptic and presynaptic dopa-
photon emission computer tomography and positron emission

Box 3 Differential diagnosis20

1. **Nocturnal leg cramps**: Sudden involuntary muscle
contractions associated with palpable tightening of the leg
muscles
2. **Akathisia**: An internal desire to move, most commonly
related to the use of neuroleptic medications; desire to move
not necessarily associated with discomfort in the legs; and
the symptoms are not worse at night
3. **Polyneuropathy**: Aetiologies include trauma, nerve
compression, diabetes, nutritional disorders, infections,
others; mostly results in sensory disturbance; may or may
not be more noticeable at night; not typically relieved by
activity
4. **Vascular insufficiency**: Primarily a consequence of
atherosclerosis; cramping-type pains that are exacerbated by
activity and improve with rest; symptoms not worse at night

(6p21.2, 2p 14, and 15q23).24 25 The genome-wide association
studies also identified variants within the intronic or intergenetic
regions of MEIS1 (2p), LBXCOR1/MAP2K5 (15q), BTBD9
(6p), neuronal nitric oxide synthase (NOS1) (12q) and protein
tyrosine phosphatase receptor type delta (9p) genes that suggest
a pathological genetic hypothesis for RLS.26 The association of
these variants in RLS is confirmed by Yang et al.,27 in
population-based and family-based case control studies in the
USA. It is interesting to note that apart from idiopathic RLS,
variants in the gene MEIS1 and BTBD9 are demonstrated to be
associated with RLS in patients with end-stage renal disease
(ESRD). This is the first study that correlated the genetic basis
in secondary RLS by Schormair et al.28

Dopaminergic system dysfunction
The symptomatic response with dopamine agonists and levo-
dopa paves the path to prove that dysfunction of the dopamin-
ergic system may play a role in the pathophysiology of the
disease.29 The role of central dopaminergic system rather than
peripheral is corroborated by the fact that administration of
peripheral dopamine antagonists does not decrease the effi-
cacy of a dopamine agonist.30 The neuroimaging studies with single
photom emission computer tomography and positron emission
tomography demonstrated a postsynaptic and presynaptic dopa-
mine receptor binding dysfunction at the level of the basal
ganglia. Some studies have shown reduced, increased and
unchanged dopamine receptor binding, thereby suggesting con-
flicting evidence of dysfunction of dopamine system.31–34
However, the diencephalospinal dopaminergic tract that origi-
nates from A11-A14 nuclei is considered as the potential ana-
tomical site of dopaminergic dysfunction. The proximity of this
system to the circadian control centres of the hypothalamus may
be the cause for the symptomatic changes of circadian pattern
diagnostic of RLS.35–37

Brain iron metabolism
There is evidence to suggest that defect in the brain iron metab-
olism may contribute to the pathogenesis of the disease. This is
supported by the fact that iron is a cofactor for tyrosine hydrox-
ylase, which is a rate-limiting step in the conversion of levo-
dopa to dopamine. Therefore decrease in iron may affect the
availability of dopamine. It has been identified that there is a
circadian variation in the activity of tyrosine hydroxylase that
may account for the worsening of symptoms in the night.38
Studies by MRI, cerebrospinal fluid and postmortem tissues
have shown the role of iron deficiency in the pathogenesis of
RLS. MRI studies have demonstrated low iron concentration in
the substantia nigra and decrease in ferritin concentrations in
the cerebrospinal fluid of patients of RLS.39 40 Another study
revealed a decrease in transferrin receptor expression in the
microvasculature of blood brain interface.41 These findings
along with the significant response observed after initiation of
iron therapy—intravenous or oral—and erythropoietin, further
supports the iron-RLS relation.42 43 An inverse relationship has
been suggested between symptom severity and serum ferritin
levels finding, which is observed in children as well.44

Role of neurotransmitters
Hypocretin-1 (orexin A) are neurotransmitters produced by
the hypothalamus that are essential for normal control of the
sleep cycle. They increase arousal and are found to interact
with the dopamine system. A study by Allen et al. has identified
that there is an increase in the hypocretin levels in the cerebro-
spinal fluid in the early onset RLS. This was the first study that
demonstrated the true difference between patients with early-onset and late-onset RLS. The authors also conclude that
elevated levels of hypocretin are responsible for the rare mani-
festations of sleep deprivation symptoms often observed in
these patients.45 46

However, a study by Stiasny-Kolster et al.47 subsequently
failed to observe any difference in hypocretin levels between
early-onset and late-onset RLS and the levels at 6 PM were not
different in patients with RLS and controls.

Inflammation and immune mechanisms
The role of inflammation and immune dysfunction was sug-
gested by studies reporting increased prevalence of small intesti-
nal bacterial overgrowth and the case reports of RLS in the
presence of infection such as HIV, Streptococcus, mycoblas-
tax, Borrelia and hepatitis C infection and connective tissue diseases
such as systemic lupus erythematosus and Sjögren’s syndrome.
The three gastrointestinal disorders, namely, Cohn’s disease,
irritable bowel disease and celiac disease are also associated with
RLS. It has been postulated that increase in hepatic levels may
trigger central nervous system (CNS) iron deficiency. Hepcidin
is a hormone produced by the liver involved in iron regulation.
Hepcidin binds with ferroportin (that export the iron from cells
into circulation) and results in its degradation. This creates a
state of systemic iron deficiency explaining the decreased iron
levels in CSF in these patients.48 49

Secondary RLS
Secondary RLS appears in later life and encumbers with greater
diagnostic challenges, especially in the presence of neurological
conditions that might mimic symptoms of RLS. A detailed neuro-
ological examination and neurophysiological studies assist in the
diagnosis.21 Box 4 lists the common causes of secondary RLS.

**CLINICAL SIGNIFICANCE OF RLS**
Patients with RLS might have a risk of developing diabetes,
hypertension, cardiovascular disease and stroke in the long
term. The possible explanation stated is sympathetic hyperactiv-
ity due to inadequate diencephalospinal dopaminergic neuron
inhibition of sympathetic preganglionic neurons.49 However,
the Women’s Health Study (WHS) and the Physicians’ Health
Box 4 Causes of secondary restless legs syndrome

- Pregnancy
- Iron deficiency anaemia
- Venous insufficiency
- Multiple sclerosis
- Parkinsonism
- Rheumatoid arthritis
- Diabetes
- Polyneuropathies
- Alcohol abuse
- Amyotrophic lateral sclerosis
- Vitamin deficiencies
- Spinal stenosis
- Excess caffeine, chocolate intake
- Lumbosacral radiculopathy
- Acute spinal cord lesions-stroke, myelitis
- Hypoglycaemia
- Hypothyroidism
- Drugs—tricyclic antidepressants, SSRI antidepressants, antiepileptic drugs, β blockers and lithium
- Obesity

Pharmacological therapy

Dopaminergic agents

These agents are used in patients who have failed to respond to the non-pharmacological approach. The dopamine agonists available for the treatment of RLS include pramipexole, ropinirole, rotigotine, cabergoline and pergolide. They directly stimulate the dopamine receptors and are generally the drug of choice in view of their lower side effects compared to the dopamine precursors.

The benefits of pramipexole and ropinirole are established in the randomised controlled trials in patients with moderate-to-severe RLS and are found to be superior to placebo as assessed by the International Restless Legs Syndrome Study (IRLS) Group rating scale. In a double-blind study by Winkelmann et al., pramipexole was found to be superior to placebo in all the three doses of 0.25 mg, 0.50 mg and 0.75 mg/day. The side effects were low with the dose of 0.25 mg daily. In a long-term follow-up study by Montplaisir et al., 78% of patients on pramipexole for more than a year, showed improvement in the RLS symptoms, which was sustained in 96% of them.

Ropinirole also demonstrated efficacy in improving the IRLS scores and increasing treatment effect with increasing severity of RLS. The other benefit of ropinirole was improvement in the global symptoms, sleep and quality of life of the patients. The common side effects encountered with these drugs included nausea, vomiting, sedation and orthostatic hypotension. The side effects were mild and transient and usually resolved in 10–14 days.

However it needs to be emphasised that augmentation is a known complication of dopaminergic medications, which translates as symptoms that occur at least 2 h prior to the usual onset of symptoms. During augmentation, the symptoms tend to intensify and spread to previously uninvolved parts of the body such as arms. Augmentation is also diagnosed in the presence of any of the two following symptoms: increase in symptoms with increase in dosage, decrease in symptoms with decrease in dosage, shortening of therapeutic benefit compared to initiation of therapy and periodic leg movements while awake either presenting or worsening. This phenomenon is probably attributed to excessive dopamine concentration in the CNS resulting in the overstimulation of D1 receptors over the D2 receptors in the spinal cord resulting in D1-related pain and periodic limb movements. Low serum ferritin levels may affect the dopamine transporter and may predispose to augmentation. The management of augmentation if patient is on levodopa includes gradually tapering the dose and substituting with medications such as dopamine agonists such as ropinirole, pramipexole that may cause augmentation but with less frequency and low intensity. The other options include dividing the drug and providing the lower dose at the earlier time of the day or increasing the total dose and providing the standard dose 1–2 h prior to the symptom onset, or if unsuccessful with the above strategies, to change to long-acting, high-potency drugs such as methadone or levorphanol.

Although Trenkwalder et al. reported no augmentation with pramipexole at the end of 9 months of use in 150 patients, there is a risk of augmentation in one-third of patients with long-term use of pramipexole. Garcia-Borreguero et al. reported a 2.3% incidence of augmentation with ropinirole in their study over a 52-week period. This complication is more frequently seen with dopamine precursors such as levodopa, and hence, the dopamine agonists are the preferred drug of choice for RLS.

INVESTIGATIONS

There are no standardised tests that are diagnostic of RLS. Measurement of iron stores with serum ferritin, total iron binding capacity, percentage of transferrin saturation, serum cobalamin (Vit B12), urea, creatinine, and glucose (haemoglobin A1C in established diabetes) can be helpful. Ferreri and Rossini, suggested that electromyography (EMG) and nerve conduction studies should be considered on the clinical grounds even in the presence of normal neurological examination. Polysomnography is required if there is suspicion of sleep disorder that helps to differentiate RLS from other sleep disorders.

MANAGEMENT

The following are the goals in the management of RLS:

1. To reduce or cure the troublesome symptoms during rest or sleep
2. Reduce the associated sleep disturbance
3. Reduce daytime fatigue or somnolence
4. Improving the quality of life

Non-pharmacological option

The non-pharmacological approach includes lifestyle modifications such as avoidance of aggravating factors like alcohol, caffeine and nicotine; mental alertness exercises (video games and reading books); stretching exercises for the posterior leg muscles; and application of heat with warm baths or heating pad. Iron replacement therapy (Ferrous sulfate 325 mg three times daily) can be suggested for patients with low serum ferritin levels (less than 50 ng/ml). Treatment of comorbid conditions is advocated in secondary RLS.
Rotigotine is a short-acting dopamine agonist available as transdermal patch. After a prospective open-label, double-blind randomised trial on rotigotine transdermal patch, done over a period of 5 years by Oertel et al, they concluded that rotigotine is safe and well tolerated, and the efficacy is sustained at a stable dose up to 5 years and can be recommended as a treatment option in moderate-to-severe RLS patients who require long-term therapy and especially with daytime symptoms. The common side effects encountered were application site reactions (58%) and clinically significant augmentation (13.2%) by the end of the 5-year study.63

The dopamine agonist pergolide is currently withdrawn from the USA due to its reported toxicity of restrictive valvular heart disease and retroperitoneal fibrosis. Hence usage of pergolide in the treatment of RLS is contraindicated.64 Cabergoline showed the study. In general, these drugs are well tolerated and the indication of opioids is as second-line agents in patients with augmentation, non-responders to dopamine therapy and in refractory RLS.71

Anticonvulsants
Gabapentin was effective in the treatment of mild-to-moderate RLS as shown by Happe et al and García-Borreguero et al. There was significant improvement in the PLMS and sleep architecture. It was identified that patients with pain, experienced relief with gabapentin. However, there were concerns regarding the side effects such as sedation, dizziness and suicidal tendencies.72 73

Studies demonstrated improvement in the symptoms of RLS including sleep architecture and mood with gabapentin enacarbil. The common adverse effects observed were mild somnolence and dizziness. 74–76 In a retrospective analysis by Ellenbogen et al there were no reports on augmentation or rebound symptoms or impulsive behaviour disorders.77 With the present encouraging evidence of good tolerability and low side-effect profile, gabapentin enacarbil is recommended for therapy for RLS.16

Two studies on the use of pregabalin (α2 delta ligand) demonstrated its effectiveness in the treatment of moderate-to-severe RLS. Allen et al reported a 90% reduction in RLS symptoms and García-Borreguero et al reported that patients on pregabalin (300 mg/day) had a 2.1% incidence of augmentation. The latter study revealed that a non-dopaminergic drug had a low incidence of augmentation.78 79

Other drugs
Although carbamazepine was effective, side effects like sedation and liver function abnormalities prevented it from being used for therapy of RLS.16 Iron supplementation was shown to be effective in the treatment of RLS patients who had low serum ferritin. Wang et al reported statistically significant improvement in patients with low serum ferritin levels with two doses of 325 mg/day of oral ferrous sulfate.30 However, Earley et al and Grote et al reported no effect with iron sucrose, and inconsistent results with the use of iron dextran.81–83 42

RLS symptoms were relieved with iron supplementation when ferritin levels were less than 50 ng/ml but there was no evidence of improvement of symptoms in patients with normal ferritin levels.33 It can be concluded that oral iron is poorly absorbed in the presence of normal body iron stores. In another study by the same author, Earley et al, in 2005, the efficacy and safety of repeated iron infusions was evaluated in RLS patients who initially demonstrated response to a single dose of iron dextran. The study revealed that supplemental iron treatments can sustain initial improvement, but not the high ferritin levels achieved after a single dose IV iron treatment. The authors highlight that rapid iron loss is probably related to pathophysiology of RLS. The data from the study therefore suggest that repeated IV dosing of iron is required to maintain treatment effectiveness.84

RLS IN PREGNANCY
The prevalence of RLS in pregnancy, as is evident from the epidemiological data, is around 11–27% with the risk of it being two to three times higher in pregnancy than the given general population. The aetiology is most likely due to altered iron metabolism during pregnancy, thereby supporting the concept of iron deficiency as the cause of RLS. The peak incidence is seen in the third trimester, which resolves after delivery. However, the risk of recurrence is 30% in subsequent pregnancies.85 86

The aim of treatment in pregnancy is to provide symptomatic relief and improve the quality of life. Non-pharmacological measures are usually advocated in mild cases and drugs are initiated only in moderate-to-severe cases. Non-pharmacological therapy like leg stretching before sleep and use of elastic stockings when associated with varicose veins have proven to be beneficial.52

**PHARMACOLOGICAL THERAPY IN PREGNANCY**

**Dopaminergic agents**
There is paucity of data on the use of dopamine agonists in pregnancy. However, there is a case report by Muñoz et al on the use of pramipexole in pregnancy with Parkinsonism, which did not show any adverse outcome. Levodopa appears to be safe in pregnancy according to the scanty evidences available.87 88

**Opioids**
There is evidence supporting the use and safety of opioids in pregnancy. The concerns are neonatal respiratory depression, especially if used in late pregnancy. Walters et al89 had considered these agents to be effective for long-term treatment with no evidence of tolerance or addiction.

**Benzodiazepines**
Benzodiazepines are considered to be effective in treating RLS in pregnancy. The concerns of risk of cleft palate, especially if used after first trimester, were shown to be negligible in a meta-analysis by Dolovich et al. Although of rare occurrence, neonatal withdrawal syndrome has been reported. The benzodiazepine of choice is clonazepam. Others such as temazepam and triazolam were also found to be effective.90 91

**Anticonvulsants**
Carbamazepine is the first anticonvulsant evaluated in the treatment of RLS. With the safety data and proven efficacy in RLS, it is a reasonable option to be considered in pregnancy. Carbamazepine to the existing drug or changing to high-potency opioid for dopamine agonists such as rotigotine transdermal patch for which long-term studies up to 5 years are available. A randomised control study has showed that pregabalin had significantly low level of augmentation. Levodopa, given the risk of augmentation, which is higher compared to dopamine agonists, has a low level of recommendation. Based on expert consensus, dopamine agonists or gabapentin or low-potency opioids are the initial choices. For intermittent RLS, the expert panel recommends levodopa or dopamine agonists or low-potency opioids or benzodiazepines. In refractory RLS, the choice is to change to gabapentin or a different dopamine agonist, addition of a second agent like gabapentin or benzodiazepine to the existing drug or changing to high-potency opioid or tramadol. There are concerns that patients with RLS are at risk of metabolic deregulation, autonomic dysfunction and cardiovascular morbidity. A recent study concluded that men or women with RLS are not at increased risk of cardiovascular complications though we need more evidence to affirm it.

**Maternal and foetal problems**
Miri S et al concluded that secondary RLS was associated low haemoglobin levels than idiopathic RLS (p=0.004). However, duration of sleep and birth weight of neonates were significantly reduced in idiopathic RLS (p=0.006 and p=0.039 respectively). There was no difference in both the groups in terms of positive family history, parity, duration of pregnancy and rate of Caesarean section. The authors surmised that idiopathic RLS can have a negative effect during pregnancy, and hence, require screening for the condition to optimise outcome.94

**Management of other secondary RLS**
The prevalence of RLS in haemodialysis patient is 6–60%. It appears to be more severe than primary RLS and is a predictor of mortality in these patients.93 96 RLS in ESRD may be related to anaemia as benefit was observed with low-dose erythropoietin and renal transplantation.146 In a randomised control study by Thorpe et al, considerable benefits were observed with gabapentin.97 The prevalence of RLS is highest among patients with Parkinsonism. The long-term anti-Parkinsonism treatment results in development of RLS. This may be attributed to the wearing-off episodes of levodopa that mimics symptoms of RLS or the augmentation effects of levodopa.98 99 Varicose veins are associated with RLS and sclerotherapy in these patients was associated with relief in 98% of these patients. Treatment with hydroxyethylrutoside in these patients demonstrated relief although not as dramatic as with sclerotherapy.100 101 Assessing serum ferritin levels and treatment of iron deficiency is of value.102 It is prudent to also incorporate lifestyle changes such as exercise, avoidance of caffeine and appropriate sleep habits along with the drugs.

**CONCLUSIONS**
There is considerable amount of advancement made in the understanding of the pathophysiological aspects and therapeutic management of this syndrome. The pathophysiology is centred on dopaminergic system dysfunction, altered iron hemostasis with decreased CNS iron, associated genetic linkages, or alteration in the neurotransmitters levels, like in hypocretins and endorphins. A new insight into this multifactorial pathophysiology is the proposed role of immune dysfunction and inflammation in the evolution of this disease process, which is richly supported by evidence. With the wide variety of pharmacological and non-pharmacological options available, it is recommended that the clinician be updated in standardising the prescription practices for symptomatic relief and to improve the quality of life in these patients. There are strong recommendations for dopamine agonists such as rotigotine transdermal patch for which long-term studies up to 5 years are available. A randomised control study has showed that pregabalin had significantly low level of augmentation. Levodopa, given the risk of augmentation, which is higher compared to dopamine agonists, has a low level of recommendation. Based on expert consensus, dopamine agonists or gabapentin or low-potency opioids are the initial choices. For intermittent RLS, the expert panel recommends levodopa or dopamine agonists or low-potency opioids or benzodiazepines. In refractory RLS, the choice is to change to gabapentin or a different dopamine agonist, addition of a second agent like gabapentin or benzodiazepine to the existing drug or changing to high-potency opioid or tramadol. There are concerns that patients with RLS are at risk of metabolic deregulation, autonomic dysfunction and cardiovascular morbidity. A recent study concluded that men or women with RLS are not at increased risk of cardiovascular complications though we need more evidence to affirm it.

**Main messages**

- Restless legs syndrome (RLS) defined by the essential criteria: (a) an urge to move the legs usually but not always associated with leg discomfort; (b) worsening of symptoms at rest, either lying or sitting; (c) partial and temporary relief of symptoms by activity; (d) worsening of symptoms later in the day or at night.
- The understanding in the pathophysiology of RLS is dopaminergic dysfunction, systemic iron deficiency, genetic linkage and more recent postulation related to inflammation and immune dysfunction.
- Dopamine agonists are currently the first line of agents in the treatment of idiopathic RLS; however, if supported with more long-term trials with other non-dopaminergic agents, the recommendation practices may change in the future.
There is a need to perform prospective studies of iron deficiency, small intestinal bacterial overgrowth and immune and inflammatory mechanisms contributing to primary and secondary RLS.

More comparative long-term trials are required between the different classes of drugs that would help to determine the efficacy and augmentation rates more effectively.

The treatment options available for idiopathic RLS do not have sufficient evidence in the management of secondary RLS. This highlights the need for randomised controlled trials to evaluate the treatment options for secondary RLS.

**REFERENCES**


**Self assessment questions**

1. In the essential criteria for RLS—The urge to move the legs that is always accompanied by unpleasant sensations of leg paraesthesia and dysesthesias

2. The dopaminergic agents levodopa/carbidopa are the first line of agents in the treatment of RLS

3. RLS symptoms are relieved with iron supplementation with ferritin levels less than 50 ng per ml

4. In patients with ESRD, RLS appears to be more severe and is a predictor of mortality in these patients

5. Recent evidence reports low augmentation risk with pregablin over other dopaminergic agents.

**Collaborators** Dr Sachchithanantham Kanagasabai.

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.


Self assessment answers

1. F
2. F
3. T
4. T
5. T